193 related articles for article (PubMed ID: 33460613)
1. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells.
Kim S; You D; Jeong Y; Yoon SY; Kim SA; Lee JE
Eur J Pharmacol; 2021 Mar; 895():173868. PubMed ID: 33460613
[TBL] [Abstract][Full Text] [Related]
2. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor α positive breast cancer.
Kim S; You D; Jeong Y; Yoon SY; Kim SA; Lee JE
Oncol Lett; 2021 Apr; 21(4):294. PubMed ID: 33732370
[TBL] [Abstract][Full Text] [Related]
4. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
5. The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
Jansson S; Aaltonen K; Bendahl PO; Falck AK; Karlsson M; Pietras K; Rydén L
Breast Cancer Res Treat; 2018 Jun; 169(2):231-241. PubMed ID: 29380207
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling.
Wang Z; Kong D; Banerjee S; Li Y; Adsay NV; Abbruzzese J; Sarkar FH
Cancer Res; 2007 Dec; 67(23):11377-85. PubMed ID: 18056465
[TBL] [Abstract][Full Text] [Related]
7. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells.
Abouantoun TJ; Castellino RC; MacDonald TJ
J Neurooncol; 2011 Jan; 101(2):215-26. PubMed ID: 20524040
[TBL] [Abstract][Full Text] [Related]
9. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
McDermott U; Ames RY; Iafrate AJ; Maheswaran S; Stubbs H; Greninger P; McCutcheon K; Milano R; Tam A; Lee DY; Lucien L; Brannigan BW; Ulkus LE; Ma XJ; Erlander MG; Haber DA; Sharma SV; Settleman J
Cancer Res; 2009 May; 69(9):3937-46. PubMed ID: 19366796
[TBL] [Abstract][Full Text] [Related]
10. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
11. PDGF-C and -D induced proliferation/migration of human RPE is abolished by inflammatory cytokines.
Li R; Maminishkis A; Wang FE; Miller SS
Invest Ophthalmol Vis Sci; 2007 Dec; 48(12):5722-32. PubMed ID: 18055825
[TBL] [Abstract][Full Text] [Related]
12. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
14. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
15. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Platelet-Derived Growth Factor and Its Receptor Are Correlated with Oral Tumorigenesis and Poor Prognosis in Oral Squamous Cell Carcinoma.
Lin LH; Lin JS; Yang CC; Cheng HW; Chang KW; Liu CJ
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235327
[TBL] [Abstract][Full Text] [Related]
17. Platelet-derived growth factor-D modulates extracellular matrix homeostasis and remodeling through TIMP-1 induction and attenuation of MMP-2 and MMP-9 gelatinase activities.
Borkham-Kamphorst E; Alexi P; Tihaa L; Haas U; Weiskirchen R
Biochem Biophys Res Commun; 2015 Feb; 457(3):307-13. PubMed ID: 25576870
[TBL] [Abstract][Full Text] [Related]
18. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer therapeutic benefit of red guava extracts as a potential therapy in combination with doxorubicin or targeted therapy for triple-negative breast cancer cells.
Liu HC; Chiang CC; Lin CH; Chen CS; Wei CW; Lin SY; Yiang GT; Yu YL
Int J Med Sci; 2020; 17(8):1015-1022. PubMed ID: 32410830
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
